Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals ...

Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, ...

Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit ...

Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the ...

Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range ...

Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET.

FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not ...

TOKYO-- (BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ...

TJ101 is an investigational bispecific ADC targeting EGFR and B7-H3, incorporating a topoisomerase I inhibitor payload. The ...

(Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and ...

The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...

ALAMEDA, Calif.-- (BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of ...